A Phase 1, Dose-Escalation/ Dose-Expansion Study Evaluating the Safety, pharmacokinetics, and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects with Lymphoid Hematological Malignancies

Type of Cancer
Hematological Malignancies

Site
Bethesda

Protocol Number
CLC-102

To Learn More Call
201-510-0910